Press release

GEAR 2023 strategic plan
Villepinte, April 18, 2018 – Guerbet (the “Company”), a global specialist in contrast agents andsolutions for medical imaging, has released today its GEAR 2023 strategic plan.

About Guerbet
Guerbet is a leading global medical imaging player. The Company engages in the research,
production and distribution of contrast media, as well as complementary medical devices andservices. Guerbet’s products are used for diagnostic purposes and increasingly for interventionalpurposes. Its activities are organized around two franchises: Diagnostic Imaging and InterventionalImaging.
In Diagnostic Imaging, Guerbet has operated a successful consolidation of its markets over the past
few years. It estimates that it is now the world #2 player in Magnetic Resonance (“MR”) imaging
contrast media, the world #4 in Computed Tomography (“CT”) and Catheterization Laboratory (“CathLab”) contrast media and the world #3 in contrast media medical devices and services. During thesame period, Guerbet has successfully diversified into Interventional Imaging, and it has a robust
R&D pipeline that is balanced across both franchises.
Guerbet reported 2017 revenue of €807.1m, representing a 4.7% growth at constant exchange rates,
and an EBITDA of €130.0m, continuing its track-record of profitable growth.

GEAR 2023 strategic plan
Guerbet has decided to implement an ambitious strategic plan to better capture growth opportunities
in a context of evolving trends in its markets.
In Diagnostic Imaging, the MR contrast media market, which is estimated to represent c. €1.0bn, isexpected to face slower growth perspectives in value with the threat of generic penetration andassociated pricing pressure that may offset the growth in volume. The CT & Cath Lab contrast media
market, which is estimated to represent c. €2.7bn, is expected to grow sustainably at a low singledigit rate. At the same time, Guerbet believes that there are significant growth opportunities inmedical devices and services for diagnostic contrast media, a market with an estimated size of c.
€1.2bn.
1

Press release
The Interventional Imaging underlying markets are underpinned by a strong drive toward minimallyinvasive surgical procedures, which require the use of contrast media. Guerbet believes that it canaddress targeted market segments with an estimated combined value in excess of c. €1.6bn,
leveraging its products portfolio and expertise. Such market segments, including interventional
oncology, interventional radiology embolization and interventional radiology delivery, wouldrepresent significant growth opportunities for Guerbet.
In order to capture growth opportunities, the GEAR 2023 strategic plan is built on four key pillars: Grow our existing products;
 Expand into adjacencies; Acquire new technologies; and Return to shareholders.
The GEAR 2023 strategic plan combines “Internal Boost” initiatives, aimed at accelerating organic
growth based on targeted investments in the current business where there are markets opportunities,
together with “External Boost” initiatives, consisting of the pursuit of acquisition opportunities in order
to compound organic growth and generate profitability accretion.
In Diagnostic Imaging, Guerbet has identified several Internal Boost and External Boost initiatives:
 Internal Boost:o P03277: targeted launch in 2022 of a new contrast media currently in development
and which is showing best-in-class potential in the Phase II B;
o Go-direct in Japan: building of own distribution platform in 2018 to accelerate
penetration in the world’s 2nd largest contrast media market for MR and CT & Cath
Lab, currently addressed through a distributor;
o Capture growth opportunities in key geographies either by accelerating in countries
recently launched after the CMDS acquisition (Poland, South Africa and Australia) orby strengthening our presence in large markets where we can seize further growth
opportunities (the US and mainland China); ando Digital offering: continued development of a modular software offering based on aSoftware as a Service (Saas) business model aimed at improving operational andclinical outcomes.
 External Boost:o Medical devices and services: strengthen the complementarity of Guerbet’s productoffering by adding new medical devices and services; ando Augmented Intelligence: develop an offering to address a strong market opportunity
leveraging on Guerbet’s network and relationships with radiologists.
In Interventional Imaging, Internal Boost initiatives will consist of the development of new indications
for Lipiodol® and the development and acceleration of Accurate Medical Therapeutics’ products,
which Guerbet has acquired in 2018.
In terms of External Boost initiatives in Interventional Imaging, Guerbet intends to build a uniqueportfolio through bolt-on acquisitions of mainly start-up players (replicating the Accurate Medical
Therapeutics model). The Company targets to generate €100m to €150m of revenue in 2023 fromcompanies acquired over 2018-2023 in Interventional Imaging. The Company believes it benefits
from strong competitive advantages to seize acquisition opportunities, including its R&D expertise to2

Press release
identify and evaluate innovative technologies from start-up companies, its commercial footprint tolaunch and accelerate their market penetration and its fast decision making for acquisition. Guerbet
has identified a pipeline of realistic targets and has the ambition to sign two acquisitions before endof 2018.
As part of GEAR 2023, Guerbet will implement a plan across its businesses to reduce costs andworking capital requirements.

Outlook and targets
For 2018, the Company expects revenue in-line with 2017 at constant exchange rates. The EBITDA
margin is expected down by c. 2 percentage points of revenue compared to 2017, due to the fullyear impact of generic competition on Dotarem®, but excluding one-off impacts. One-off impacts
related to the integration of Accurate Medial Therapeutics and the transition to an own distribution
platform in Japan are expected to decrease EBITDA by c. €10m in 2018. The Company expects toproceed with net capital expenditure in the range of c. €50m and to have a neutral to slightly positivechange in net working capital, despite one-off impacts. In 2018, the Company will pay the upfront
consideration of €19.5m associated with the Accurate Medical Therapeutics acquisition, as well aspart of the up to €37.5m earn-out consideration, which is to be paid in several installments over2018-2020, subject to performance conditions.
For 2020, and taking into account Internal Boost initiatives only, the Company targets revenue
between €850m and €900m at constant exchange rates and an EBITDA margin above 16.5%. The
Company targets net capital expenditure of c. €50m with an additional one-off impact of c. €10m in
2020 and 2021, consisting of the roll-out of the Group’s ERP across CMDS businesses. Regarding
working capital, the Company targets to decrease requirements as percentage of revenue back topre-CMDS acquisition level.
For 2023, and taking into account Internal Boost initiatives only, the Company targets revenue ofaround c. €1.0bn at constant exchange rates and an EBITDA margin above 20%. The Companytargets net capital expenditure of c. €50m.
External Boost initiatives to be achieved over 2018-2023 are targeted to contribute an additional€150m to €250m of revenue by 2023 and to have an overall positive impact on EBITDA margin.
Regarding the financial policy over 2018-2023, the Company intends to maintain its net debt toEBITDA ratio below 3.5x at all times, to maintain its dividend distribution policy with a pay-out ratio
target in the range of 25% to 35% and to optimize shareholders’ return.

3

Press release
Disclaimer
Certain information included in this press release and other statements or materials published by the Company
are not historical facts but are forward-looking statements. These forward-looking statements refer in particular
to the Company’s management’s business strategies, its expansion and growth of operations, future events,
trends or objectives and expectations, which are naturally subject to risks and contingencies that may lead toactual results materially differing from those explicitly or implicitly included in these statements.
Forward-looking statements speak only as of the date of this press release and, subject to any legalrequirement, the Company does not undertake to update or revise the forward-looking statements that may
be presented in this press release to reflect new information, future events or for any other reason and any
opinion expressed in this press release is subject to change without notice. Such forward looking statements
are for illustrative purposes only. Forward-looking information and statements are not guarantees of future
performances and are subject to various risks and uncertainties, many of which are difficult to predict andgenerally beyond the control of the Company. These risks and uncertainties include among other things, theuncertainties inherent in research and development of new products, including future clinical trial results andanalysis of clinical data (including post-marketing data), decisions by regulatory authorities, such as the Foodand Drug Administration or the European Medicines Agency, regarding whether and when to approve any
drug, device or biological application that may be filed for any such product candidates as well as theirdecisions regarding labelling and other matters that could affect the availability or commercial potential of suchproduct candidates. A detailed description of risks and uncertainties related to the Company’s activities isincluded under Chapter 4.3 “Risk factors” in the Registration Document (Document de Référence) of theCompany which has been filed with the French Financial Markets Authority on April 5, 2017 under the number
n°D-17-0323 and is available on the Company’s website (www.guerbet.com).
This press release contains statistics, data and other information relating to markets, market sizes, marketshares, market growth, market positions and other industry data pertaining to the Company’s business andmarkets. Such information is based on the Company’s analysis of multiple internal and third party sources,
including information extracted from market research, governmental and other publicly available information,
independent industry publications and information and reports. The Company, its affiliates, shareholders,
directors, officers, advisors, employees and representatives have not independently verified the accuracy of
any such market data and industry forecasts. Such data and forecasts are included in this press release forinformation purposes only.
Some of the financial information contained in this press release is not directly extracted from the Company’s
accounting systems or records and does not constitute International Financial Reporting Standards (IFRS)
accounting measures, including in particular EBITDA. The Company calculates EBITDA as operating income,with the net allowance for amortization, depreciation and provisions added back in. EBITDA is not a measureof financial performance under IFRS and the definition of the term used by the Company may not becomparable to similar terms used by other companies. Such information has not been independently reviewed
or verified by the Company’s auditors.
This press release does not contain or constitute an offer of securities for sale or an invitation or inducement
to invest in securities in France, the United States or any other jurisdiction.

4